Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in…
KIELPIN, Poland, June 22, 2021 (GLOBE NEWSWIRE) -- Celon Pharma today announced filing for approval to start a Phase II clinical study of CPL’280, its second generation GPR40 agonist in type 2 diabetes. This double-blind, randomized,…